These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27222538)

  • 1. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
    Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
    Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis.
    Kessler BE; Mishall KM; Kellett MD; Clark EG; Pugazhenthi U; Pozdeyev N; Kim J; Tan AC; Schweppe RE
    Oncogene; 2019 Apr; 38(14):2565-2579. PubMed ID: 30531837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.
    Hicks HM; McKenna LR; Espinoza VL; Pozdeyev N; Pike LA; Sams SB; LaBarbera D; Reigan P; Raeburn CD; E Schweppe R
    Mol Carcinog; 2021 Mar; 60(3):201-212. PubMed ID: 33595872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
    Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R
    Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model.
    Scott AJ; Song EK; Bagby S; Purkey A; McCarter M; Gajdos C; Quackenbush KS; Cross B; Pitts TM; Tan AC; Eckhardt SG; Fenton H; Arcaroli J; Messersmith WA
    PLoS One; 2017; 12(11):e0187173. PubMed ID: 29091939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
    Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
    Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.
    Kim SM; Kim H; Jang KW; Kim MH; Sohn J; Yun MR; Kang HN; Kang CW; Kim HR; Lim SM; Moon YW; Kim JH; Paik S; Cho BC
    Mol Cancer Ther; 2016 Jul; 15(7):1627-36. PubMed ID: 27196768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    Leboeuf R; Baumgartner JE; Benezra M; Malaguarnera R; Solit D; Pratilas CA; Rosen N; Knauf JA; Fagin JA
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2194-201. PubMed ID: 18381570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011; 4(170):er2. PubMed ID: 21674991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
    Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
    Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.